AGILE THERAPEUTICS INC (AGRX)
US00847L3087 - Common Stock
AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023
AGRX stock results show that Agile Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Agile Therapeutics (NASDAQ:AGRX) just reported results for the fourth quarter o...
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Agile Therapeutics Announces Delisting from Nasdaq
Agile Therapeutics Announces Delisting from Nasdaq
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare...
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Live Conference Call and Webcast at 8:30 a.m. ET
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Live Conference Call and Webcast at 8:30 a.m. ET...
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
Live Conference Call and Webcast at 8:30 a.m. ET
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
Live Conference Call and Webcast at 8:30 a.m. ET...
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt Free
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt Free...
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare...
Why Is Bel Fuse (BELFB) Stock Down 17% Today?
Bel Fuse stock is falling on Thursday as investors in BELFB shares react to the company's lackluster Q4 2023 earnings report.
Why Is Draganfly (DPRO) Stock Down 48% Today?
Draganfly stock is down on Thursday after the company announced details for a $3.6 million public offering of DPRO shares.
Why Is BuzzFeed (BZFD) Stock Up 101% Today?
BuzzFeed stock is rising higher on Thursday as investors in BZFD react to it selling Complex for $108.6 million in cash.
Why Is Agile Therapeutics (AGRX) Stock Up 87% Today?
Agile Therapeutics stock is rising higher on Thursday with heavy trading of AGRX shares despite a lack of news from the company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we're starting the day with a breakdown of all the latest news this morning!
Agile Therapeutics reports higher prelim FY revenue than last year (NASDAQ:AGRX)
Agile Therapeutics expects an 84%-93% increase in net revenue for 2023, while operating expenses are projected to decrease by 44%-47%.
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 ...
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow...
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report...